Biotech of the Week: Activartis Immuno-Oncology in Vienna

08/04/2016 - 1 minute

This week, we leave Milan and head once again towards the East. Vienna: Austria’s palatial and stunning capital city is our destination, and is also where our Biotech of the week, Activartis, is located.

activartis_logo_biotech_week

City: Vienna (Austria)

Founded: 2003

Employees: 11 – 50 (as of 12/2015)

Financial Data: N/A

CEO: Thomas Felzmann

activartis_ceo_biotech_week

Mission: Currently in phase II clinical trials, Activartis is trying to develop a new cancer immunotherapy based on dendritic cells. Their main goal is to treat an aggressive form of brain tumor, but also being able to use this treatment on several other types of cancer.

The company’s therapeutic platform gathers an innovative proprietary approach via a bacterial danger signal combined with tumor antigens. By applying this concept, the use of dendritic cells to mobilise the patient’s immune system to treat cancer was proven successful.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member